Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.
Zannad F, Stough WG, Lipicky RJ, Tamargo J, Bakris GL, Borer JS, Alonso García Mde L, Hadjadj S, Koenig W, Kupfer S, McCullough PA, Mosenzon O, Pocock S, Scheen AJ, Sourij H, Van der Schueren B, Stahre C, White WB, Calvo G. Zannad F, et al. Among authors: van der schueren b. Eur Heart J Cardiovasc Pharmacother. 2016 Jul;2(3):200-5. doi: 10.1093/ehjcvp/pvw007. Epub 2016 Apr 3. Eur Heart J Cardiovasc Pharmacother. 2016. PMID: 27418973 Free PMC article. Review.
Using provocative design to foster electronic informed consent innovation.
De Sutter E, Verreydt S, Yskout K, Geerts D, Borry P, Outtier A, Ferrante M, Vandermeulen C, Vanmechelen N, Van der Schueren B, Huys I. De Sutter E, et al. Among authors: van der schueren b. BMC Med Inform Decis Mak. 2022 Nov 17;22(1):296. doi: 10.1186/s12911-022-02039-6. BMC Med Inform Decis Mak. 2022. PMID: 36397108 Free PMC article.
Otelixizumab in the treatment of type 1 diabetes mellitus.
Sprangers B, Van der Schueren B, Gillard P, Mathieu C. Sprangers B, et al. Among authors: van der schueren b. Immunotherapy. 2011 Nov;3(11):1303-16. doi: 10.2217/imt.11.123. Immunotherapy. 2011. PMID: 22053883
New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk.
Graham I, Shear C, De Graeff P, Boulton C, Catapano AL, Stough WG, Carlsson SC, De Backer G, Emmerich J, Greenfeder S, Kim AM, Lautsch D, Nguyen T, Nissen SE, Prasad K, Ray KK, Robinson JG, Sasiela WJ, Bruins Slot K, Stroes E, Thuren T, Van der Schueren B, Velkovski-Rouyer M, Wasserman SM, Wiklund O, Zouridakis E; European Society of Cardiology Cardiovascular Roundtable. Graham I, et al. Among authors: van der schueren b. Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):119-127. doi: 10.1093/ehjcvp/pvx031. Eur Heart J Cardiovasc Pharmacother. 2018. PMID: 29194462 Review.
Obesity in people living with type 1 diabetes.
Van der Schueren B, Ellis D, Faradji RN, Al-Ozairi E, Rosen J, Mathieu C. Van der Schueren B, et al. Lancet Diabetes Endocrinol. 2021 Nov;9(11):776-785. doi: 10.1016/S2213-8587(21)00246-1. Epub 2021 Sep 30. Lancet Diabetes Endocrinol. 2021. PMID: 34600607 Review.
Cereulide food toxin, beta cell function and diabetes: Facts and hypotheses.
Vangoitsenhoven R, Maris M, Overbergh L, Van Loco J, Mathieu C, Van der Schueren B. Vangoitsenhoven R, et al. Among authors: van loco j, van der schueren b. Diabetes Res Clin Pract. 2015 Jul;109(1):1-5. doi: 10.1016/j.diabres.2015.04.029. Epub 2015 May 6. Diabetes Res Clin Pract. 2015. PMID: 25998918 Review.
In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions.
Mbunwe E, Van der Auwera BJ, Weets I, Van Crombrugge P, Crenier L, Coeckelberghs M, Seret N, Decochez K, Vandemeulebroucke E, Gillard P, Keymeulen B, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry. Mbunwe E, et al. Diabetologia. 2013 Sep;56(9):1964-70. doi: 10.1007/s00125-013-2951-8. Epub 2013 May 28. Diabetologia. 2013. PMID: 23712485 Free PMC article.
180 results